{"id":248611,"date":"2026-09-16T11:15:24","date_gmt":"2026-09-16T05:45:24","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=248611"},"modified":"2026-09-16T11:15:24","modified_gmt":"2026-09-16T05:45:24","slug":"regulated-markets-pharma-stock-rises-104-percent-in-1-year","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/regulated-markets-pharma-stock-rises-104-percent-in-1-year\/","title":{"rendered":"This Regulated Markets Pharma Stock Rises 104% in 1 Year: What Is Driving the Re-Rating?"},"content":{"rendered":"

CMP approximately Rs 1,403 (16 Sep 2026). 1-year return 104%. 52W range Rs 662.45 to Rs 1,599. Market cap Rs 6,543 Cr. FY26 PAT Rs 122 Cr vs Rs 58 Cr.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Senores Pharmaceuticals is the regulated markets pharma stock behind a verified 1-year price return of approximately 104%, computed from a close of Rs 686.50 on 16 September 2025 to about Rs 1,403 on 16 September 2026. The gain came from a US and Canada business that now contributes around 71% of revenue, an approved ANDA count that rose from 30 to 58 in a year, and FY26 profit that roughly doubled to Rs 122 crore. At a PE near 50 against an industry PE of about 38, the next leg depends on execution.<\/p>\n<\/div>\n

This regulated markets pharma stock has delivered a price return of approximately 104% in one year, turning Rs 1 lakh into roughly Rs 2.04 lakh. The figure is a close to close calculation from Rs 686.50 on 16 September 2025 to about Rs 1,403 on 16 September 2026, with no split or bonus in between. That made it one of the strongest performers on a screen of NSE small-cap stocks ranked by 1-year return, dated 16 September 2026.<\/p>\n

The company is Senores Pharmaceuticals Ltd<\/a><\/strong> (NSE: SENORES), an Ahmedabad based drugmaker that listed in December 2024 and sells mainly into the United States and Canada. Unlike many recent listings that faded after a few months, this regulated markets pharma stock kept compounding on quarterly numbers. It buys or files approved product dossiers, plugs them into owned manufacturing, and sells where regulatory barriers keep competition limited.<\/p>\n

Click Here – Get Free Investment Predictions<\/a><\/strong><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n